A case of dupilumab‐induced psoriasis‐like eruption treated with baricitinib
Abstract Dupilumab is a humanized monoclonal antibody against the interleukin (IL)‐4 receptor alpha chain that inhibits IL‐4 and IL‐13 signalling. It is one of the systemic treatments for patients with moderate‐to‐severe atopic dermatitis (AD), which provides favourable safety and efficacy. We repor...
Main Authors: | Yuki Kinoshita, Hisayoshi Imanishi, Tomoko Oshimo, Daisuke Tsuruta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | Skin Health and Disease |
Online Access: | https://doi.org/10.1002/ski2.338 |
Similar Items
-
Psoriasis‐like eruptions developed in an atopic dermatitis patient treated with dupilumab
by: Rai Fujimoto, et al.
Published: (2022-12-01) -
Subcutaneous panniculitis-like T-cell lymphoma and steroid-induced depression successfully treated with prednisolone and cyclosporine
by: Tomoko Oshimo, et al.
Published: (2023-01-01) -
Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions
by: Laura Kern, et al.
Published: (2022-11-01) -
Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab
by: Mingxia Wang, et al.
Published: (2022-06-01) -
Fixed Drug Eruption due to Dupilumab
by: Ayaka Kaneoka, et al.
Published: (2024-04-01)